☆ 4.7 Article

Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer

CLINICAL CHEMISTRY (2021)

Related references

Note: Only part of the references are listed.

Article Oncology

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy

L. Du et al.

Summary: The SET2,3 test measures transcription related to estrogen and progesterone receptors and provides independent prognostic information in predicting distant relapse-free survival for patients with stage II-III breast cancer. It adds valuable information to chemotherapy response and baseline prognostic score or subtype, highlighting its potential role in guiding clinical treatment decisions, especially for high-risk HR+/HER2- disease. Other molecular signatures were not independently prognostic but could substitute for RNA4 subtype within the BPI component of SET2,3. SETER/PR index was found to be an important component of SET2,3 and could not be effectively substituted by other molecular signatures.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Medical Laboratory Technology

Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue

Rosanna Lau et al.

CLINICAL CHEMISTRY (2020)

Add to Collection

Article Medical Laboratory Technology

Inadequate Reporting of Analytical Characteristics of Biomarkers Used in Clinical Research: A Threat to Interpretation and Replication of Study Findings

Qian Sun et al.

CLINICAL CHEMISTRY (2019)

Add to Collection

Article Oncology

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

Bruno Sinn et al.

NPJ BREAST CANCER (2019)

Add to Collection

Article Medicine, General & Internal

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Hongchao Pan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

Minetta C. Liu et al.

NPJ BREAST CANCER (2016)

Add to Collection

Article Oncology

A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes

Benjamin Haibe-Kains et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)

Add to Collection

Article Oncology

Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer

W. Fraser Symmans et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Kathy S. Albain et al.

LANCET ONCOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.